Although BTLA is typically considered an inhibitory receptor, this upregulation may reflect a compensatory, yet ultimately insufficient, attempt to regulate disease activity, consistent with previous studies linking BTLA expression on B cells with modulation of MS severity (48). Here, BTLA is linked to myeloid sarcoma.